Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
119 tokens/sec
GPT-4o
56 tokens/sec
Gemini 2.5 Pro Pro
43 tokens/sec
o3 Pro
6 tokens/sec
GPT-4.1 Pro
47 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Towards quantum computing for clinical trial design and optimization: A perspective on new opportunities and challenges (2404.13113v1)

Published 19 Apr 2024 in quant-ph and cs.ET

Abstract: Clinical trials are pivotal in the drug discovery process to determine the safety and efficacy of a drug candidate. The high failure rates of these trials are attributed to deficiencies in clinical model development and protocol design. Improvements in the clinical drug design process could therefore yield significant benefits for all stakeholders involved. This paper examines the current challenges faced in clinical trial design and optimization, reviews established classical computational approaches, and introduces quantum algorithms aimed at enhancing these processes. Specifically, the focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification. This study aims to provide a comprehensive framework that leverages quantum computing to innovate and refine the efficiency and effectiveness of clinical trials.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (183)
  1. Paul Adrien Maurice Dirac. The principles of quantum mechanics, 1981.
  2. Werner Heisenberg. Development of concepts in the history of quantum theory. In The physicist’s conception of nature, pages 264–275. Springer, 1973.
  3. Peter W Shor. Algorithms for quantum computation: discrete logarithms and factoring. In Proceedings 35th annual symposium on foundations of computer science, pages 124–134. Ieee, 1994.
  4. Lov K Grover. A fast quantum mechanical algorithm for database search. In Proceedings of the twenty-eighth annual ACM symposium on Theory of computing, pages 212–219, 1996.
  5. Quantum algorithm for linear systems of equations. Physical review letters, 103(15):150502, 2009.
  6. A polynomial quantum algorithm for approximating the jones polynomial. In Proceedings of the thirty-eighth annual ACM symposium on Theory of computing, pages 427–436, 2006.
  7. Quantum algorithms for topological and geometric analysis of data. Nature communications, 7(1):10138, 2016.
  8. Seth Lloyd. Universal quantum simulators. Science, 273(5278):1073–1078, 1996.
  9. Why 90 Acta Pharm Sin B., 2022.
  10. Artificial intelligence for clinical trial design. Trends in pharmacological sciences, 40(8):577–591, 2019.
  11. Clinical trial failures in inflammatory bowel disease: An artificial intelligence-assisted review. Official journal of the American College of Gastroenterology | ACG, 118(10), 2023.
  12. Benchmarking patient recruitment and retention practices. Therapeutic Innovation & Regulatory Science, 55(1):19–32, 2021.
  13. Food and Drug Administration. Enrichment strategies for clinical trials to support approval of human drugs and biological products. Technical report, Center for Drug Evaluation and Research, 2019.
  14. David B. Fogel. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun, 11:156–164, 2018. Place: Netherlands.
  15. Innovation in the pharmaceutical industry: new estimates of r&d costs. Journal of health economics, 47:20–33, 2016.
  16. Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2):273–286, 2019.
  17. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. Jama, 323(9):844–853, 2020.
  18. Identification of in vitro and in vivo disconnects using transcriptomic data. BMC genomics, 16:1–10, 2015.
  19. In vitro–in vivo correlations: general concepts, methodologies and regulatory applications. Drug development and industrial pharmacy, 41(12):1935–1947, 2015.
  20. Human organoids: model systems for human biology and medicine. Nature Reviews Molecular Cell Biology, 21(10):571–584, 2020.
  21. The path to personalized medicine. New England Journal of Medicine, 363(4):301–304, 2010.
  22. Critical path activities in clinical trial setup and conduct: How to avoid bottlenecks and accelerate clinical trials. Drug Discovery Today, 28(10):103733, 2023.
  23. Do eligibility criteria restrict access to clinical trials? Journal of Clinical Oncology, 38(29_suppl):94–94, 2020.
  24. Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsA Systematic Sampling Review. JAMA, 297(11):1233–1240, 03 2007.
  25. Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement. Journal of Clinical Oncology, 35(33):3737–3744, 2017. PMID: 28968170.
  26. Jennifer Abbasi. Older Patients (Still) Left Out of Cancer Clinical Trials. JAMA, 322(18):1751–1753, 11 2019.
  27. Juno Obedin-Maliver. Time to change: Supporting sexual and gender minority people—an underserved, understudied cancer risk population. Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 15(11):1305 – 1308, 2017.
  28. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control, 23(4):327–337, 2016. PMID: 27842322.
  29. Food and Drug Aministration. Enhancing the diversity of clinical trial populations — eligibility criteria, enrollment practices, and trial designs guidance for industry. Technical report, 2020.
  30. Modernizing eligibility criteria for molecularly driven trials. Journal of Clinical Oncology, 33(25):2815–2820, 2015. PMID: 26195710.
  31. Assessing population diversity in phase iii trials of cancer drugs supporting food and drug administration approval in solid tumors. International journal of cancer, 149(7):1455–1462, 2021.
  32. Health equity in the implementation of genomics and precision medicine: A public health imperative. Genetics in Medicine, 24(8):1630–1639, 2022.
  33. Ancestry matters: Building inclusivity into preclinical study design. Cell, 184(10):2525–2531, 2021.
  34. Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews. Contemporary Clinical Trials Communications, 23:100829, 2021.
  35. Prognostic and predictive enrichment in sepsis. Nature Reviews Nephrology, 16(1):20–31, Jan 2020.
  36. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit. Care Med., 44(10):e1000–3, October 2016.
  37. Stefan Harrer. Measuring life: sensors and analytics for precision medicine. In Sander van den Driesche, editor, Bio-MEMS and Medical Microdevices II, volume 9518, page 951802. International Society for Optics and Photonics, SPIE, 2015.
  38. A review of approaches to identifying patient phenotype cohorts using electronic health records. Journal of the American Medical Informatics Association, 21(2):221–230, 11 2013.
  39. Adjusting for selection bias in retrospective, case–control studies. Biostatistics, 10(1):17–31, 05 2008.
  40. Cohort selection for clinical trials from longitudinal patient records: text mining approach. JMIR medical informatics, 7(4):e15980, 2019.
  41. Strategies for handling missing data in electronic health record derived data. eGEMs, 1, 2013.
  42. Children’s rare disease cohorts: an integrative research and clinical genomics initiative. npj Genomic Medicine, 5(1):29, Jul 2020.
  43. Multimodal machine learning in precision health: A scoping review. npj Digital Medicine, 5(1):171, Nov 2022.
  44. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? an analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 12(1):44, Mar 2017.
  45. Synthetic and external controls in clinical trials–a primer for researchers. Clinical epidemiology, pages 457–467, 2020.
  46. Cross-trial prediction in psychotherapy: External validation of the personalized advantage index using machine learning in two dutch randomized trials comparing cbt versus ipt for depression. Psychotherapy Research, 31(1):78–91, 2021. PMID: 32964809.
  47. Explainable ai enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia. BMC Medical Informatics and Decision Making, 21(1):162, May 2021.
  48. Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate. Frontiers in Psychiatry, 12:741170, 2021.
  49. Digitizing clinical trials. NPJ digital medicine, 3(1):101, 2020.
  50. Advancing models and theories for digital behavior change interventions. American journal of preventive medicine, 51(5):825–832, 2016.
  51. Sample size calculations for micro-randomized trials in mhealth. Statistics in medicine, 35(12):1944–1971, 2016.
  52. Applied concepts in pbpk modeling: how to build a pbpk/pd model. CPT: pharmacometrics & systems pharmacology, 5(10):516–531, 2016.
  53. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. Journal of pharmacokinetics and pharmacodynamics, 43:481–504, 2016.
  54. Physiologically-based pharmacokinetics in drug development and regulatory science. Annual review of pharmacology and toxicology, 51:45–73, 2011.
  55. Applications of linking pbpk and pd models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Frontiers in pharmacology, 5:258, 2014.
  56. Population-based mechanistic prediction of oral drug absorption. The AAPS journal, 11:225–237, 2009.
  57. The utility of modeling and simulation in drug development and regulatory review. Journal of pharmaceutical sciences, 102(9):2912–2923, 2013.
  58. Overview of therapeutic drug monitoring. The Korean journal of internal medicine, 24(1):1, 2009.
  59. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. Drug metabolism and disposition, 39(7):1278–1287, 2011.
  60. Factors influencing clinical trial site selection in europe: the survey of attitudes towards trial sites in europe (the sat-eu study). BMJ open, 3(11), 2013.
  61. A review of multi-criteria decision making applications for renewable energy site selection. Renewable Energy, 157:377–403, 2020.
  62. Landfill site selection by using geographic information systems. Environmental geology, 49:376–388, 2006.
  63. A fuzzy multi-criteria decision-making method for facility site selection. The International Journal of Production Research, 29(11):2313–2330, 1991.
  64. Portfolio approach to optimize site selection. Applied Clinical Trials, 2019.
  65. Framm: Fair ranking with missing modalities for clinical trial site selection. arXiv preprint arXiv:2305.19407, 2023.
  66. Philippe Jorion. Portfolio optimization in practice. Financial analysts journal, 48(1):68–74, 1992.
  67. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results. BMJ Open, 7(7), 2017.
  68. Doctor2vec: Dynamic doctor representation learning for clinical trial recruitment. arXiv preprint arXiv:1911.10395, 2019.
  69. Optimizing clinical trials recruitment via deep learning. Journal of the American Medical Informatics Association, 26(11):1195–1202, 06 2019.
  70. Clinical trial site matching with improved diversity using fair policy learning. arXiv preprint arXiv:2204.06501, 2022.
  71. Pytrial: Machine learning software and benchmark for clinical trial applications. arXiv preprint arXiv:2306.04018, 2023.
  72. A knowledge graph of clinical trials. Sci Rep, 2022.
  73. A survey on knowledge graphs for healthcare: Resources, applications, and promises. arXiv preprint arXiv:2306.04802, 2023.
  74. Cohort selection for clinical trials using deep learning models. Journal of the American Medical Informatics Association, 26(11):1181–1188, 2019.
  75. Machine learning models based on a national-scale cohort identify patients at high risk of prolonged length of stay following primary total hip arthroplasty. The Journal of Arthroplasty, 2023.
  76. A hybrid approach for data clustering based on modified cohort intelligence and k-means. Expert Systems with Applications, 41(13):6009–6016, 2014.
  77. Behrt: transformer for electronic health records. Scientific reports, 10(1):7155, 2020.
  78. Generative adversarial networks. Communications of the ACM, 63(11):139–144, 2020.
  79. Ganeraid: Realistic synthetic patient data for clinical trials. Informatics in Medicine Unlocked, 35:101118, 2022.
  80. Creating synthetic patient data using a generative adversarial network having a multivariate gaussian generative model, March 14 2024. US Patent App. 17/930,477.
  81. Generative adversarial networks. Commun. ACM, 63(11):139–144, oct 2020.
  82. Integrated multimodal artificial intelligence framework for healthcare applications. npj Digital Medicine, 5(1):149, Sep 2022.
  83. Artificial intelligence-based methods for fusion of electronic health records and imaging data. Scientific Reports, 12(1):17981, 2022.
  84. Clinical trial design in the era of precision medicine. Genome medicine, 14(1):101, 2022.
  85. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precision Oncology, 1:1–12, 2019.
  86. Prediction of treatment outcome in clinical trials under a personalized medicine perspective. Scientific Reports, 12(1):4115, Mar 2022.
  87. US Food. Drug administration. enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products guidance for industry. Administration FD, editor. Silver Spring: Center for Drug Evaluation and Research, pages 1–41, 2019.
  88. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nature communications, 13(1):2922, 2022.
  89. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation, 135(22):2091–2101, 2017.
  90. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. The Lancet, 385(9984):2264–2271, 2015.
  91. Role of genetics in capturing racial disparities in cardiovascular disease. medRxiv, pages 2023–02, 2023.
  92. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature genetics, 51(4):584–591, 2019.
  93. Global biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. Cell Genomics, 3(1), 2023.
  94. Polygenic prediction via bayesian regression and continuous shrinkage priors. Nature communications, 10(1):1776, 2019.
  95. Fairprs: adjusting for admixed populations in polygenic risk scores using invariant risk minimization. In Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, volume 28, page 198. NIH Public Access, 2023.
  96. Ai-enabled evaluation of genome-wide association relevance and polygenic risk score prediction in alzheimer’s disease. Iscience, 27(3), 2024.
  97. Application of machine learning methods in clinical trials for precision medicine. JAMIA open, 5(1):ooab107, 2022.
  98. Towards quantum-enabled cell-centric therapeutics, 2023.
  99. Improving variational quantum optimization using cvar. Quantum, 4:256, 2020.
  100. Quantum optimization using variational algorithms on near-term quantum devices. Quantum Science and Technology, 3(3):030503, 2018.
  101. A practitioner’s guide to quantum algorithms for optimisation problems. Journal of Physics A: Mathematical and Theoretical, 56(45):453001, 2023.
  102. Variational quantum algorithms. Nature Reviews Physics, 3(9):625–644, 2021.
  103. Quantum optimization: Potential, challenges, and the path forward. arXiv preprint arXiv:2312.02279, 2023.
  104. Quantum algorithms: A survey of applications and end-to-end complexities, 2023.
  105. An introduction to quantum machine learning. Contemporary Physics, 56(2):172–185, 2015.
  106. Quantum machine learning. Nature, 549(7671):195–202, 2017.
  107. Challenges and opportunities in quantum machine learning. Nature Computational Science, 2(9):567–576, 2022.
  108. Quantum convolutional neural networks. Nature Physics, 15(12):1273–1278, 2019.
  109. Unsupervised machine learning on a hybrid quantum computer. arXiv preprint arXiv:1712.05771, 2017.
  110. The second quantum revolution: role and challenges of molecular chemistry. Journal of the American Chemical Society, 141(29):11339–11352, 2019.
  111. Nonadiabatic nuclear–electron dynamics: a quantum computing approach. The Journal of Physical Chemistry Letters, 14(31):7065–7072, 2023.
  112. Toward accurate post-born–oppenheimer molecular simulations on quantum computers: An adaptive variational eigensolver with nuclear-electronic frozen natural orbitals. Journal of Chemical Theory and Computation, 19(24):9269–9277, 2023.
  113. A quantum computing implementation of nuclearelectronic orbital (neo) theory: Toward an exact pre-born–oppenheimer formulation of molecular quantum systems. The Journal of Chemical Physics, 158(21), 2023.
  114. Hardware-efficient variational quantum eigensolver for small molecules and quantum magnets. nature, 549(7671):242–246, 2017.
  115. Quantum computation of dominant products in lithium–sulfur batteries. The Journal of Chemical Physics, 154(13), 2021.
  116. Doubling the size of quantum simulators by entanglement forging. PRX Quantum, 3(1):010309, 2022.
  117. Quantum simulations of molecular systems with intrinsic atomic orbitals. Physical Review A, 106(2):022404, 2022.
  118. Quantum chemistry simulation of ground-and excited-state properties of the sulfonium cation on a superconducting quantum processor. Chemical Science, 14(11):2915–2927, 2023.
  119. Simulation of a diels-alder reaction on a quantum computer. arXiv preprint arXiv:2403.08107, 2024.
  120. Quantum embedding method for the simulation of strongly correlated systems on quantum computers. The Journal of Physical Chemistry Letters, 14(14):3491–3497, 2023.
  121. Quantum algorithms for quantum chemistry and quantum materials science. Chemical Reviews, 120(22):12685–12717, 2020.
  122. Crystals-dilithium: A lattice-based digital signature scheme. IACR Transactions on Cryptographic Hardware and Embedded Systems, pages 238–268, 2018.
  123. Assessing the benefits and risks of quantum computers, 2024.
  124. A tutorial on formulating and using qubo models. arXiv preprint arXiv:1811.11538, 2018.
  125. Multiblock admm heuristics for mixed-binary optimization on classical and quantum computers. IEEE Transactions on Quantum Engineering, 1:1–22, 2020.
  126. Quantum machine learning framework for virtual screening in drug discovery: a prospective quantum advantage. Machine Learning: Science and Technology, 4(1):015023, 2023.
  127. A perspective on protein structure prediction using quantum computers, 2023.
  128. Quantum computing for finance: Overview and prospects. Reviews in Physics, 4:100028, 2019.
  129. Efficient parameter optimisation for quantum kernel alignment: A sub-sampling approach in variational training. arXiv preprint arXiv:2401.02879, 2024.
  130. Hideaki Kawaguchi. Application of quantum computing to a linear non-gaussian acyclic model for novel medical knowledge discovery. PLOS ONE, 18(4):e0283933, 2023.
  131. Frederik F Flöther. The state of quantum computing applications in health and medicine. Research Directions: Quantum Technologies, 1:e10, 2023.
  132. Physiologically based in silico models for the prediction of oral drug absorption. Drug Absorption Studies: In Situ, In Vitro and In Silico Models, pages 486–509, 2008.
  133. Ivan Nestorov. Whole body pharmacokinetic models. Clinical Pharmacokinetics, 42(10):883–908, 2003.
  134. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. Journal of Biomedicine and Biotechnology, 2011, 2011.
  135. Data management in clinical research: an overview. Indian journal of pharmacology, 44(2):168, 2012.
  136. Vivek Subbiah. The next generation of evidence-based medicine. Nature medicine, 29(1):49–58, 2023.
  137. Generalization in quantum machine learning from few training data. Nature communications, 13(1):4919, 2022.
  138. Understanding quantum machine learning also requires rethinking generalization. Nature Communications, 15(1):1–12, 2024.
  139. Encoding-dependent generalization bounds for parametrized quantum circuits. Quantum, 5:582, 2021.
  140. Generalization in quantum machine learning: A quantum information standpoint. PRX Quantum, 2(4):040321, 2021.
  141. Power of data in quantum machine learning. Nature communications, 12(1):2631, 2021.
  142. The power of quantum neural networks. Nature Computational Science, 1(6):403–409, 2021.
  143. Concentration of data encoding in parameterized quantum circuits. Advances in Neural Information Processing Systems, 35:19456–19469, 2022.
  144. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics, 97(3):247–262, 2015.
  145. A new approach to decoding life: systems biology. Annual review of genomics and human genetics, 2(1):343–372, 2001.
  146. Metabolomics: available results, current research projects in breast cancer, and future applications. Journal of clinical oncology, 25(19):2840–2846, 2007.
  147. Sheila Annie Peters. Physiologically based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. John Wiley & Sons, 2021.
  148. HM Jones and Karen Rowland-Yeo. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: pharmacometrics & systems pharmacology, 2(8):1–12, 2013.
  149. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Current drug metabolism, 10(10):1192–1199, 2009.
  150. High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. Journal of pharmaceutical sciences, 93(4):816–830, 2004.
  151. Quantum algorithm for nonlinear differential equations. arXiv preprint arXiv:2011.06571, 2020.
  152. Efficient quantum algorithm for dissipative nonlinear differential equations. Proceedings of the National Academy of Sciences, 118(35):e2026805118, 2021.
  153. Hari Krovi. Improved quantum algorithms for linear and nonlinear differential equations. Quantum, 7:913, 2023.
  154. Does provable absence of barren plateaus imply classical simulability? or, why we need to rethink variational quantum computing. arXiv preprint arXiv:2312.09121, 2023.
  155. Exponential concentration and untrainability in quantum kernel methods. arXiv preprint arXiv:2208.11060, 2022.
  156. Let quantum neural networks choose their own frequencies. arXiv preprint arXiv:2309.03279, 2023.
  157. Quantum kernel methods for solving regression problems and differential equations. Physical Review A, 107(3):032428, 2023.
  158. Physics-informed quantum machine learning: Solving nonlinear differential equations in latent spaces without costly grid evaluations. arXiv preprint arXiv:2308.01827, 2023.
  159. Quantum computational finance: quantum algorithm for portfolio optimization, 2018.
  160. Quantum machine learning in feature hilbert spaces. Physical review letters, 122(4):040504, 2019.
  161. Quantum kernels for real-world predictions based on electronic health records. IEEE Transactions on Quantum Engineering, 3:1–11, 2022.
  162. Supervised learning with quantum-enhanced feature spaces. Nature, 567(7747):209–212, 2019.
  163. Quantum machine learning applied to electronic healthcare records for ischemic heart disease classification. Human-centric Computing and Information Sciences, 13:17, 02 2023.
  164. Quantum machine learning for untangling the real-world problem of cancers classification based on gene expressions. bioRxiv, 2023.
  165. Medical image classification via quantum neural networks, 2022.
  166. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des. Devel. Ther., page 5215, September 2015.
  167. Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors. Comput Struct Biotechnol J, 21:3912–3919, July 2023.
  168. Integrative analysis of multi-omics and genetic approaches—a new level in atherosclerotic cardiovascular risk prediction. Biomolecules, 11(11), 2021.
  169. Power of data in quantum machine learning. Nature Communications, 12(1):2631, May 2021.
  170. Supervised learning with quantum-enhanced feature spaces. Nature, 567(7747):209–212, Mar 2019.
  171. Emergent order in classical data representations on ising spin models, 2023.
  172. Representation theory for geometric quantum machine learning, 2023.
  173. Theory for equivariant quantum neural networks, 2022.
  174. The inductive bias of quantum kernels. In Neural Information Processing Systems, 2021.
  175. Theoretical guarantees for permutation-equivariant quantum neural networks. npj Quantum Information, 10:12, 2024.
  176. Rotation equivariant cnns for digital pathology. In Alejandro F. Frangi, Julia A. Schnabel, Christos Davatzikos, Carlos Alberola-López, and Gabor Fichtinger, editors, Medical Image Computing and Computer Assisted Intervention – MICCAI 2018, pages 210–218, Cham, 2018. Springer International Publishing.
  177. The art of using t-sne for single-cell transcriptomics. Nature Communications, 10(1):5416, Nov 2019.
  178. Generalization in quantum machine learning from few training data. Nature Communications, 13(1):4919, Aug 2022.
  179. Quantum generative adversarial learning. Phys. Rev. Lett., 121:040502, Jul 2018.
  180. Qugan: A quantum state fidelity based generative adversarial network. In 2021 IEEE International Conference on Quantum Computing and Engineering (QCE). IEEE, October 2021.
  181. Quantum generative adversarial networks for learning and loading random distributions. npj Quantum Information, 5(1):103, Nov 2019.
  182. Evidence for the utility of quantum computing before fault tolerance. Nature, 618(7965):500–505, 2023.
  183. High-threshold and low-overhead fault-tolerant quantum memory. Nature, 627(8005):778–782, 2024.
User Edit Pencil Streamline Icon: https://streamlinehq.com
Authors (13)
  1. Hakan Doga (5 papers)
  2. M. Emre Sahin (30 papers)
  3. Joao Bettencourt-Silva (4 papers)
  4. Anh Pham (20 papers)
  5. Eunyoung Kim (2 papers)
  6. Alan Andress (1 paper)
  7. Sudhir Saxena (1 paper)
  8. Aritra Bose (6 papers)
  9. Laxmi Parida (15 papers)
  10. Jan Lukas Robertus (4 papers)
  11. Hideaki Kawaguchi (11 papers)
  12. Radwa Soliman (1 paper)
  13. Daniel Blankenberg (4 papers)

Summary

We haven't generated a summary for this paper yet.

Ai Sparkles Streamline Icon: https://streamlinehq.com Summarize Now